

## STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (FG-43)	EMIPLACEL
PRONUNCIATION	em" i pla' sel
THERAPEUTIC CLAIM	Treatment of critical limb ischemia, intermittent claudication, Buerger's Disease, and muscle injury following hip arthroplasty

### CHEMICAL DESCRIPTION

Allogenic ex-vivo expanded placental adherent stromal cells

### STRUCTURAL FORMULA

PLX-PAD cells are characterized by a high expression of CD105, CD73 and CD29, and absence of expression of CD45, CD34, CD14, CD19, and HLA DR surface molecules. In addition, PLX-PAD cells do not express CD31 (endothelial cell marker), GlyA (erythrocyte cell marker), or co-stimulatory markers (CD80, CD86 and CD40) on their membrane. PLX-PAD cells are spindle shaped when they adhere to plastic. All attributes of PLX-PAD cells were found on cell samples that had undergone cryopreservation and thawing.

While PLX-PAD cells exhibit membrane marker expression typical of classical mesenchymal stromal cells, they have a minimal ability to differentiate *in vitro* into cells of mesodermal lineage.

PLX-PAD cells are expanded in the manufacturing facility to no more than 25 population doublings from the original extraction of placental cells until cryopreservation of the final cell product. If passaged *in vitro*, the final PLX-PAD cells reach senescence within ~37 additional population doublings, while maintaining a stable karyotype.

PLX-PAD has been shown to secrete factors that affect angiogenesis, immunomodulation and muscle regeneration.

TRADEMARK	None as yet
SPONSOR	Pluristem, Ltd.
CODE DESIGNATION	PLX-PAD
UNII	DPX6XLD4X1
WHO NUMER	10628

SCS